Kyle A. Beckwith

2.2k total citations · 1 hit paper
18 papers, 681 citations indexed

About

Kyle A. Beckwith is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Kyle A. Beckwith has authored 18 papers receiving a total of 681 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 8 papers in Pathology and Forensic Medicine and 7 papers in Immunology. Recurrent topics in Kyle A. Beckwith's work include Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (7 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Kyle A. Beckwith is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), Lymphoma Diagnosis and Treatment (7 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Kyle A. Beckwith collaborates with scholars based in United States, Austria and Australia. Kyle A. Beckwith's co-authors include John C. Byrd, Natarajan Muthusamy, Jennifer A. Woyach, Amy J. Johnson, Leslie A. Andritsos, Kami J. Maddocks, Amy M. Lehman, Joseph M. Flynn, Carolyn Cheney and Priscilla Do and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Neuroscience and Blood.

In The Last Decade

Kyle A. Beckwith

18 papers receiving 676 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ibrutinib treatment improves T cell number and function in CLL patients

2017 288 citations Meixiao Long, Kyle A. Beckwith et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kyle A. Beckwith United States	10	391	300	269	222	164	18	681
Lisa Bonello Italy	11	428 1.1×	195 0.7×	312 1.2×	247 1.1×	279 1.7×	15	842
Rogier Mous Netherlands	11	174 0.4×	308 1.0×	245 0.9×	392 1.8×	155 0.9×	35	723
Katherine Chung United States	9	56 0.1×	223 0.7×	236 0.9×	200 0.9×	167 1.0×	13	661
John Densmore United States	10	202 0.5×	257 0.9×	337 1.3×	219 1.0×	154 0.9×	27	712
Peter Kjellén Sweden	12	174 0.4×	93 0.3×	415 1.5×	88 0.4×	163 1.0×	16	652
Jack Y. Lee United States	11	135 0.3×	66 0.2×	341 1.3×	207 0.9×	264 1.6×	17	762
Jesús Gutiérrez‐Abril Spain	4	253 0.6×	187 0.6×	137 0.5×	65 0.3×	287 1.8×	8	537
Nduka Amankulor United States	4	209 0.5×	75 0.3×	305 1.1×	240 1.1×	164 1.0×	7	600
Chiara Dell’Agnola Italy	10	95 0.2×	56 0.2×	252 0.9×	295 1.3×	361 2.2×	12	659
Edith Szafer‐Glusman United States	14	321 0.8×	384 1.3×	163 0.6×	343 1.5×	173 1.1×	58	829

Countries citing papers authored by Kyle A. Beckwith

Since Specialization

Citations

This map shows the geographic impact of Kyle A. Beckwith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle A. Beckwith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle A. Beckwith more than expected).

Fields of papers citing papers by Kyle A. Beckwith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle A. Beckwith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle A. Beckwith. The network helps show where Kyle A. Beckwith may publish in the future.

Co-authorship network of co-authors of Kyle A. Beckwith

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle A. Beckwith. A scholar is included among the top collaborators of Kyle A. Beckwith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle A. Beckwith. Kyle A. Beckwith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Kittai, Adam S., Ying Huang, Kyle A. Beckwith, et al.. (2022). Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib. American Journal of Hematology. 98(1). 56–65. 8 indexed citations

Kittai, Adam S., Cecelia Miller, Ying Huang, et al.. (2021). The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood. 138(23). 2372–2382. 31 indexed citations

Kittai, Adam S., Ying Huang, Kyle A. Beckwith, et al.. (2021). Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib. Blood. 138(Supplement 1). 3731–3731. 2 indexed citations

Goldstein, Daniel J., Kyle A. Beckwith, Cecelia Miller, et al.. (2020). Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Blood. 136(Supplement 1). 2–3. 1 indexed citations

Do, Priscilla, Kyle A. Beckwith, Carolyn Cheney, et al.. (2019). Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells. The Journal of Immunology. 202(9). 2806–2816. 22 indexed citations

Long, Meixiao, Kyle A. Beckwith, Priscilla Do, et al.. (2017). Ibrutinib treatment improves T cell number and function in CLL patients. Journal of Clinical Investigation. 127(8). 3052–3064. 288 indexed citations breakdown →

Do, Priscilla, Kyle A. Beckwith, Larry Beaver, et al.. (2016). Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis. Blood. 128(22). 3221–3221. 3 indexed citations

Long, Meixiao, Kyle A. Beckwith, Priscilla Do, et al.. (2016). Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism. Blood. 128(22). 3238–3238. 3 indexed citations

Hing, Zachary A., Rose Mantel, Kyle A. Beckwith, et al.. (2015). Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood. 125(20). 3128–3132. 72 indexed citations

10.

Gensel, John C., Yan Wang, Zhen Guan, et al.. (2015). Toll-Like Receptors and Dectin-1, a C-Type Lectin Receptor, Trigger Divergent Functions in CNS Macrophages. Journal of Neuroscience. 35(27). 9966–9976. 56 indexed citations

11.

Beckwith, Kyle A., John C. Byrd, & Natarajan Muthusamy. (2015). Tetraspanins as therapeutic targets in hematological malignancy: a concise review. Frontiers in Physiology. 6. 91–91. 45 indexed citations

12.

Long, Meixiao, Kyle A. Beckwith, Kami J. Maddocks, et al.. (2015). Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients. Blood. 126(23). 2940–2940. 3 indexed citations

13.

Beckwith, Kyle A., et al.. (2015). The Role of Tetraspanin CD37 in B-Cell Malignancy. Blood. 126(23). 1258–1258. 2 indexed citations

14.

Beckwith, Kyle A., Frank Frissora, Matthew Stefanovski, et al.. (2014). The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 28(7). 1501–1510. 29 indexed citations

15.

Ling, Yonghua, Jennifer A. Woyach, Kyle A. Beckwith, et al.. (2014). OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood. 125(2). 284–295. 21 indexed citations

16.

Zhong, Yi, Dalia El‐Gamal, Jason A. Dubovsky, et al.. (2014). Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. Leukemia. 28(5). 1158–1163. 45 indexed citations

17.

Stephens, Deborah M., Kyle A. Beckwith, Carolyn Cheney, et al.. (2014). BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia. Blood. 124(21). 4681–4681. 4 indexed citations

18.

Hertlein, Erin, Kyle A. Beckwith, Gerard Lozanski, et al.. (2013). Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease. PLoS ONE. 8(10). e76607–e76607. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact